Analysts aren’t too concerned by an apparent stock sell-off at former BD Diabetes unit Embecta (Nasdaq:EMBC).
Our sister site, Drug Delivery Business News, reports today that BTIG analysts like the direction in which Embecta is heading, despite a few recent hurdles.
Those hurdles include the discontinuation of the company’s insulin patch pump product line, as well as layoffs and restructuring as a result. However, BTIG’s Marie Thibault, Sam Eiber and Alexandra Pang spoke with Embecta CEO Devdatt Kurdikar, CFO Jake Elguicze, and head of investor relations Pravesh Khandelwal earlier this week and say the company is heading in the right direction and think that the stock sell-off in the past two days is unwarranted.”
Thibault, Eiber and Pang covered some of the recent developments at Embecta, plus what the future may hold for the company.
Get the full story at our sister site, Drug Delivery Business News.